Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

Recent & Breaking News (TSX:TH)

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

GlobeNewswire October 17, 2024

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

GlobeNewswire October 17, 2024

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024

GlobeNewswire October 10, 2024

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV

GlobeNewswire October 9, 2024

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire September 26, 2024

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

GlobeNewswire September 17, 2024

Theratechnologies to Present at Upcoming Investor Conferences in September

GlobeNewswire September 9, 2024

Theratechnologies stock jumps on positive income report

Jonathon Brown July 10, 2024

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

GlobeNewswire July 10, 2024

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire June 26, 2024

Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

GlobeNewswire May 23, 2024

Theratechnologies Reports on its Annual Meeting of Shareholders

GlobeNewswire May 9, 2024

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

GlobeNewswire May 2, 2024

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

GlobeNewswire April 15, 2024

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 11, 2024

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

GlobeNewswire April 10, 2024

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology(TM) Oncology Platform

GlobeNewswire April 8, 2024

Theratechnologies Appoints Elina Tea to its Board of Directors

GlobeNewswire April 5, 2024

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire April 3, 2024

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platform

GlobeNewswire March 28, 2024